Liver function may change how lung cancer drug works

NCT ID NCT07538973

First seen Apr 28, 2026 · Last updated Apr 28, 2026

Summary

This early-stage study looks at how the drug anecatibin fumarate behaves in people with lung cancer who have different levels of liver function. Researchers will compare drug levels and safety in 24 adults with either impaired or normal liver function. The goal is to understand if liver problems change how the drug is processed, which can guide future dosing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Qingdao University Affiliated Hospital

    Qingdao, Shandong, 266000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Xiamen Traditional Chinese Medicine Hospital

    Xiamen, Fujian, 361000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhengzhou Sixth People's Hospital

    Zhengzhou, Henan, 450015, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.